Abingdon Life Sciences, Inc. Enters Into Alliance With Stason Pharmaceuticals, Inc. to Provide Regulatory and Clinical Support
Abingdon Life Sciences, Inc. has entered into an agreement with Stason Pharmaceuticals, Inc to provide clinical and regulatory support for Stason?s drug development programs.
Abingdon Life Sciences, Inc. Enters Into Strategic Alliance With Stason Pharmaceuticas, Inc. to Provide Regulatory and Clinical Support.
Carlsbad, CA, August 4th, 2008: Abingdon Life Sciences, Inc. has entered into an agreement with Stason Pharmaceuticals, Inc to provide clinical and regulatory support for Stason’s drug development programs. As part of the agreement, Abingdon will provide clinical and regulatory services for Stason’s pipeline of potential drug candidates and devices in the areas of cancer and inflammation.
“We are extremely happy to have formalized our relationship with Stason, and believe that this represents a synergistic opportunity for both our companies to leverage our respective core competencies in drug development and manufacturing”, said Richard Lebovitz, Abingdon CEO. Harry Fan, CEO of Stason added “Stason is pleased to have agreed to this strategic partnership with Abingdon. It is a mutually beneficial relationship bringing expertise in many areas to our clients, both here in the US and in our overseas markets”.
About Abingdon Life Sciences, Inc.:
Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development ManagementOrganization (DDMO) providing drug and device companies superior clinical and regulatoryservices based on an integrated strategic development model. Abingdon's senior executivesprovide personalized oversight and leadership of projects to ensure the best possiblecustomer experience.
About Stason Pharmaceuticals, Inc.:
Founded in 1994, Stason Pharmaceuticals, Inc. has evolved into a vertically integrated cGMP contract development organization with affiliates and locations in Texas, Massachusetts, Japan, China and Taiwan that provide complete turn-key drug development solutions for API, prototype and final product, clinical supplies for all phases, and commercial production and distribution. Stason also out-licenses internally developed technologies to companies worldwide. Stason is specialized in developing and processing high-potency products, including oncology drugs.
For More Information Contact:Abingdon Contact:
Aidan Nuttall, Ph.D.
(1) 760-268-1078
[email protected]
Stason Contact:
Diana Wood
(1) 760-929-0346
[email protected]
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
